The neuroimaging of the post-traumatic stress disorder patients by losing their relative before and after the treatment

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046475

Enrollment

Unknown

Registered

2021-05-16

Start date

2021-05-31

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic stress disorder

Interventions

Group of only drug:Paroxetine Hydrochloride Tablets

Drug+ high frequence rTMS:Paroxetine Hydrochloride Tablets +high frequence rTMS

Drug+ low frequence rTMS:Paroxetine Hydrochloride Tablets +low frequence rTMS

Drug+ rTMS sham:Paroxetine Hydrochloride Tablets +sham rTMS

Eligibility

Sex/Gender

All

Age

45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 45 to 65 years; 2. Loss of immediate family; no other trauma; 3. PTSD diagnosis by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders and Clinician-Administered PTSD Scale (CAPS), and without any treatment.

Exclusion criteria

Exclusion criteria: 1. Depression, anxiety, schizophrenia, and other mental disorders other than PTSD (Hamilton Depression HAMD, anxiety HAMA, and other scales); 2. Alcohol and drug abuse; 3. Organic brain diseases; 4. History of coma due to head trauma; 5. Obvious physical diseases and cognitive decline; Contraindications related to MRI examination.

Design outcomes

Primary

Measure	Time frame
Scale score;Neuroimaging;	—

Countries

China

Contacts

Public ContactCao Zhihong

Yixing People Hospital

staff877@yxph.com+86 510 87921010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026